Light-Activated Tool Helps to Better Understand Diabetes Drugs

Light Activated Tools

 

May 07 2016

Sandra Henderson

Researchers at the University of Birmingham (UK) have developed a light-activated tool to show how drugs need to be adapted to combat type 2 diabetes. 

The study, published in Angewandte Chemie, provides insight into the signalling process of receptors in cells. The findings could lead to a new generation of anti-diabetic drugs that are activated by either blue or ultra-violet light. 

David Hodson, PhD, from Birmingham’s Institute of Metabolism and Systems Research, explains the new light-activated tool that could help optimize T2D drugs: “The GLP-1 receptor is involved in the maintenance of normal glucose levels and is presently targeted by a number of blockbuster T2D drugs,” the expert says. “However, the function of this receptor is poorly understood. In particular, drugs that bind a ‘hidden’ allosteric site may be safer and more specific alternatives to present therapies.” 

Hodson further notes that production of such drugs is at present hindered by the lack of information about how the allosteric site works. “Together with Dirk Trauner and Johannes Broichhagen at LMU Munich, we have designed a new drug, termed PhotoETP, whose conformation and binding can be controlled by light,” he reports. “This allows us to understand precisely the interactions that need to occur between a molecule and the allosteric site for full operation.” 

Researchers able to change conformation/activity of positive allosteric modulator using light  

The promising research breaks new ground in the realm of light-activated tools for optimizing drugs. “PhotoETP is termed a positive allosteric modulator,” says Hodson. “While these exist, no one has been able to change their conformation or activity using light. We have done this by incorporating an azobenzene photoresponsive element that undergoes isomerization following illumination.” 

The expert confirms that the innovation could, in fact, catalyze a new generation of drugs activated by blue or ultraviolet light. “We have already produced a range of light-activated anti-diabetics that target ion channels and G protein coupled receptors,” he says. “The aim of PhotoETP is to provide a tool that allows allosteric signalling at the GLP-1 receptor to be properly understood, with implications for the rationale design of drugs that will supersede the incretin-mimetics due to their improved safety and efficacy.” 

Photopharmacology evolves 
The findings could represent a photopharmacological stepping stone on the path to light-activated drugs of the future. “Light-activated antibiotics, chemotherapeutics and anti-diabetics have all been produced,” Hodson notes. “These studies are further evidence that, one day, photopharmacology — the targeting of drug activity in space and time — may become inherent to drug design and disease treatment.” 

In that endeavour, Hodson and his team are well underway toward realizing light-activated anti-diabetics. “We have begun to synthesize variants of PhotoETP that will provide further clues as to how the GLP-1 receptor works,” he reveals. “Moreover, we are performing proof-of-concept experiments to show that light-activated anti-diabetics can be safely used in vivo to control blood glucose levels.” 

Sandra Henderson is Research Editor, Novus Light Technologies Today.

 Photo: novuslight.com

Related Articles


Changing Scene

  • July 10, 2025 - Mac’s II Agencies Announce Addition to Project & Specification Sales Team

    Mac’s II Agencies Announces Addition to Project & Specification Sales Team

    Mac’s II Agencies is pleased to announce that Drazen Jerkovic will be joining their Project & Specification Sales team in the Lighting Division later this fall. With over 25 years of experience in the lighting and electrical industry, Drazen is a highly respected consultant known for his technical knowledge and deep understanding of project delivery. His recent role… Read More…

  • Noramco-Announces-Samantha-Boernsen-as-New-Regional-Sales-Manager-Winnipeg

    Noramco Announces Samantha Boernsen as New Regional Sales Manager, Winnipeg

    Please join Noramco in welcoming Samantha Boernsen as Regional Sales Manager, Winnipeg! Samantha brings a wealth of experience in the electrical industry, with a strong focus on lighting, marketing strategy, and customer engagement. She has built her career on connecting technical expertise with real-world application, making her a trusted partner to clients and colleagues alike.… Read More…


Design


New Products

  • Cooper Lighting Solutions: Metalux CZL Cruze Linear Bay

    Cooper Lighting Solutions: Metalux CZL Cruze Linear Bay

    The CZL Cruze is a Linear Bay LED Lighting System that comes in various lumen packages and configurations, offering customer-focused features and benefits such as integrated controls, uplight, several lensing options, louvers and adjustable mounting. The high performance, lighting distribution and linear design allows the CZL to fit a broad range of open-ceiling or suspended… Read More…

  • ABB Emergi-Lite: ELFT Series – Fast Transfer Emergency Lighting Inverter System 1.5KVA –16.7KVA

    ABB Emergi-Lite: ELFT Series – Fast Transfer Emergency Lighting Inverter System 1.5KVA –16.7KVA

    The ELFT Series is easy to install and maintain with a single point for testing and servicing. Specialized for emergency lighting it uses a solid-state pulse width modulation inverter to provide pure sinusoidal output waveform. With its user-friendly LCD display, programmable monthly and annual self-testing, and an automatic test, event, and alarm log help keep… Read More…